Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

177 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Analysis of molecular and clinical markers of resistance to bacillus of Calmette-Guérin immunotherapy in patients with urothelial non-muscle invasive bladder cancer.
DI Maida F, Grosso AA, Tellini R, Lambertini L, Lo Re M, Cadenar A, Giudici S, Giorgione R, Rossi V, Antonuzzo L, Minervini A, Mari A. DI Maida F, et al. Among authors: antonuzzo l. Minerva Urol Nephrol. 2022 Oct;74(5):642-646. doi: 10.23736/S2724-6051.22.04959-X. Minerva Urol Nephrol. 2022. PMID: 36125025 Free article. No abstract available.
Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study.
Qin S, Chan SL, Gu S, Bai Y, Ren Z, Lin X, Chen Z, Jia W, Jin Y, Guo Y, Hu X, Meng Z, Liang J, Cheng Y, Xiong J, Ren H, Yang F, Li W, Chen Y, Zeng Y, Sultanbaev A, Pazgan-Simon M, Pisetska M, Melisi D, Ponomarenko D, Osypchuk Y, Sinielnikov I, Yang TS, Liang X, Chen C, Wang L, Cheng AL, Kaseb A, Vogel A; CARES-310 Study Group. Qin S, et al. Lancet. 2023 Sep 30;402(10408):1133-1146. doi: 10.1016/S0140-6736(23)00961-3. Epub 2023 Jul 24. Lancet. 2023. PMID: 37499670 Clinical Trial.
Pembrolizumab for First-Line Treatment of Advanced Non-Small-Cell Lung Cancer: Analysis of Prognostic Factors of Outcomes.
Tibaldi C, Mazzoni F, Scotti V, Vasile E, Pozzessere D, Stasi I, Camerini A, Federici F, Meoni G, Caparello C, Turrini M, Rossi V, Ciccone LP, Pecora I, Fantechi B, Antonuzzo L, Giannarelli D, Baldini E. Tibaldi C, et al. Among authors: antonuzzo l. Anticancer Agents Med Chem. 2022;22(7):1278-1285. doi: 10.2174/1871520621666210727112212. Anticancer Agents Med Chem. 2022. PMID: 34315390
Occurrence of Dysgeusia in Patients Being Treated for Cancer.
Di Meglio J, Dinu M, Doni L, Rossi G, Giorgione R, Colombini B, Antonuzzo L, Sofi F. Di Meglio J, et al. Among authors: antonuzzo l. Nutr Cancer. 2022;74(8):2868-2874. doi: 10.1080/01635581.2022.2042569. Epub 2022 Feb 23. Nutr Cancer. 2022. PMID: 35196919
Effect of systemic therapies or best supportive care after disease progression to both nivolumab and cabozantinib in metastatic renal cell carcinoma: The Meet-Uro 19BEYOND study.
Roviello G, Gambale E, Giorgione R, Santini D, Stellato M, Fornarini G, Rebuzzi SE, Basso U, Bimbatti D, Doni L, Nesi G, Bersanelli M, Buti S, De Giorgi U, Galli L, Sbrana A, Conca R, Carella C, Naglieri E, Pignata S, Procopio G, Antonuzzo L. Roviello G, et al. Among authors: antonuzzo l. Cancer Med. 2022 Aug;11(16):3084-3092. doi: 10.1002/cam4.4681. Epub 2022 Mar 20. Cancer Med. 2022. PMID: 35312175 Free PMC article.
177 results